Comparison Overview

Inspire Pharma

VS

MENARINI Group

Inspire Pharma

4 El Tahrir St, Sheraton Heliopolis sheraton heliopolis Cairo, EG
Last Update: 2025-03-14 (UTC)
View Profile
Between 800 and 849
http://www.inspirepharma.com

Inspire pharma is a national Egyptian pharmaceutical company established in 2005, founded by a determined group of partners to be a unique business model in the healthcare industry in Egypt. After a three-year ride in legislative and licensing processes, we were successful in acquiring distinguished talents at several levels to drive and deliver organizational KPIs. Together with 100 molecules cued up in the pipeline 15 molecules were launched successfully since 2010 . Our management team is not only emphasizing the financial objectives, but rather, it’s equally determined to establish a unique business culture and inspiring code of conduct through our core values.

NAICS: 325
NAICS Definition:
Employees: 201-500
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

MENARINI Group

Via dei Sette Santi 1/3, Firenze, Italy, 50131, IT
Last Update: 2025-03-06 (UTC)
Between 750 and 799
https://www.menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

NAICS: 325
NAICS Definition:
Employees: 12,100
Subsidiaries: 26
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/inspire-pharma.jpeg
Inspire Pharma
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/menarini.jpeg
MENARINI Group
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Inspire Pharma
100%
Compliance Rate
0/4 Standards Verified
MENARINI Group
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Inspire Pharma in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MENARINI Group in 2025.

Incident History — Inspire Pharma (X = Date, Y = Severity)

Inspire Pharma cyber incidents detection timeline including parent company and subsidiaries

Incident History — MENARINI Group (X = Date, Y = Severity)

MENARINI Group cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/inspire-pharma.jpeg
Inspire Pharma
Incidents

No Incident

https://images.rankiteo.com/companyimages/menarini.jpeg
MENARINI Group
Incidents

No Incident

FAQ

Inspire Pharma company demonstrates a stronger AI Cybersecurity Score compared to MENARINI Group company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, MENARINI Group company has disclosed a higher number of cyber incidents compared to Inspire Pharma company.

In the current year, MENARINI Group company and Inspire Pharma company have not reported any cyber incidents.

Neither MENARINI Group company nor Inspire Pharma company has reported experiencing a ransomware attack publicly.

Neither MENARINI Group company nor Inspire Pharma company has reported experiencing a data breach publicly.

Neither MENARINI Group company nor Inspire Pharma company has reported experiencing targeted cyberattacks publicly.

Neither Inspire Pharma company nor MENARINI Group company has reported experiencing or disclosing vulnerabilities publicly.

Neither Inspire Pharma nor MENARINI Group holds any compliance certifications.

Neither company holds any compliance certifications.

MENARINI Group company has more subsidiaries worldwide compared to Inspire Pharma company.

MENARINI Group company employs more people globally than Inspire Pharma company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Inspire Pharma nor MENARINI Group holds SOC 2 Type 1 certification.

Neither Inspire Pharma nor MENARINI Group holds SOC 2 Type 2 certification.

Neither Inspire Pharma nor MENARINI Group holds ISO 27001 certification.

Neither Inspire Pharma nor MENARINI Group holds PCI DSS certification.

Neither Inspire Pharma nor MENARINI Group holds HIPAA certification.

Neither Inspire Pharma nor MENARINI Group holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References